BofA raised the firm’s price target on Cardinal Health (CAH) to $155 from $150 and keeps a Buy rating on the shares. The recent introduction of tariffs on China and India, combined with the current administration’s changes to the FDA, could “create a perfect storm leading to generic inflation,” says the analyst, who highlights upside in the case of generic inflation for Cardinal, McKesson (MCK) and Cencora (COR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $150 from $142 at Mizuho
- Cardinal Health: Strong Fundamentals and Growth Prospects Justify Buy Rating Despite Tariff Concerns
- Cardinal Health call volume above normal and directionally bullish
- Cardinal Health Appoints New Independent Directors
- Elliott exits Cardinal Health, cuts NRG Energy in Q4